Personalised medicine in upper GI cancers

Speaker: Michel P. Ducreux

M. Ducreux says that the main focus of genomic research in upper GI cancers is in gastric carcinoma. He emphasizes that understanding of carcinogenesis is key in achieving progress in the treatment and discusses molecular subtypes of gastric cancer. He predicts that in a near future oncologists will be able to select patients and to propose immunotherapy probably in a sub-population of patients with MSI type gastric carcinoma.

Discussion Points

  • What is the main focus of genomic research in upper GI cancers?
  • How is the research currently translating  into clinical utility for patients with upper GI cancers?
  • Describe the impact of some of the specific considerations of upper GI cancers on personalised medicine – for example, greater heterogeneity, greater prevalence of mutations and unusual amplification patterns
  • What impact does inflammation have on personalised medicine for upper GI cancers?
  • Describe some of the most recent research on personalised medicine targeting upper GI cancer subtypes based on specific pathways and potential clinical vulnerabilities for both prevention and treatment
  • What is the future outlook of personalised medicine in upper GI cancers?